Federal Register / Vol. 75, No. 8 / Wednesday, January 13, 2010 / Notices 1813 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than February 12, 2010. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–504 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances Notice of Registration 

By Notice dated August 28, 2009, and 

published in the Federal Register on 

September 8, 2009, (74 FR 46231), Cody 

Laboratories, 601 Yellowstone Avenue, 

Cody, Wyoming 82414, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Drug Schedule 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans on manufacturing 

the listed controlled substances in bulk 

for sale to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of Cody 

Laboratories to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Cody 

Laboratories to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–511 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 28, 2009, and 

published in the Federal Register on 

September 8, 2009, (74 FR 46231), 

Chemic Laboratories, Inc., 480 Neponset 

Street, Building 7, Canton, 

Massachusetts 02021, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of Cocaine (9041), 

a basic class of controlled substance 

listed in schedule II. 

The company plans to manufacture 

small quantities of the above listed 

controlled substance for distribution to 

its customers for the purpose of 

research. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Chemic Laboratories to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated Chemic 

Laboratories to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–515 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated September 14, 2009, 

and published in the Federal Register 

on September 18, 2009, (74 FR 47962), 

GE Healthcare, 3350 North Ridge 

Avenue, Arlington Heights, Illinois 

60004–1412, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of Cocaine (9041), 

a basic class of controlled substance 

listed in schedule II. 

The company plans to manufacture a 

radioactive product used in diagnostic 

imaging in the diagnosis of Parkinson’s 

Disease and for manufacture in bulk for 

investigational new drug (IND) 

submission and clinical trials. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of GE 

Healthcare to manufacture the listed 

basic class of controlled substance is 

consistent with the public interest at 

this time. DEA has investigated GE 

Healthcare to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 


srobinson on DSKHWCL6B1PROD with NOTICES
1814 Federal Register / Vol. 75, No. 8 / Wednesday, January 13, 2010 / Notices 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–509 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 28, 2009 and 

published in the Federal Register on 

September 8, 2009, (74 FR 46232), 

Noramco Inc., Division of Ortho McNeil, 

Inc., 500 Swedes Landing Road, 

Wilmington, Delaware 19801–4417, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Noroxymorphone (9668), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to bulk 

manufacture the listed controlled 

substance as a reference standard for 

distribution to its customers which are 

analytical laboratories. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Noramco Inc. to manufacture the listed 

basic class of controlled substance is 

consistent with the public interest at 

this time. DEA has investigated 

Noramco Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–508 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 28, 2009, and 

published in the Federal Register on 

September 8, 2009, (74 FR 46233), 

National Center for Natural Products 

Research-NIDA MProject, University of 

Mississippi, 135 Coy Waller Lab 

Complex, University, Mississippi 38677, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

I: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to cultivate 

marihuana for the National Institute on 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

National Center for Natural Products 

Research-NIDA MProject to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated National Center for Natural 

Products Research-NIDA MProject to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: January 6, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–506 Filed 1–12–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

National Institute of Corrections 

Solicitation for a Cooperative 

Agreement—Curriculum Development: 

Training for Correctional Industries 

Directors 

AGENCY: National Institute of 

Corrections, Department of Justice. 

ACTION: Solicitation for a cooperative 

agreement. 

SUMMARY: The National Institute of 

Corrections’ (NIC) Transition and 

Offender Workforce Development (T/ 

OWD) and Academy Divisions are 

seeking applications for the 

development of a competency based, 

blended modality training curriculum 

that will provide Correctional Industries 

Directors with the knowledge, skills and 

abilities needed to set organizational 

priorities, identify strategic objectives, 

create measurable goals, establish 

collaborative partnerships, utilize 

current labor market information, and 

provide specialized services and 

programming that support the offenders’ 

long term attachment to the labor force. 

DATES: Applications must be received 

by 4 p.m. EST on Friday, February 12, 

2010. 

ADDRESSES: Mailed applications must be 

sent to: Director, National Institute of 

Corrections, 320 First Street, NW., Room 

5007, Washington, DC 20534. 

Applicants are encouraged to use 

Federal Express, UPS, or similar service 

to ensure delivery by the due date. 

Hand delivered applications should 

be brought to 500 First Street, NW., 

Washington, DC 20534. At the front 

desk, dial 7–3106, extension 0 for 

pickup. 

Faxed applications will not be 

accepted. Electronic applications can be 

submitted via http://www.grants.gov. 

FOR FURTHER INFORMATION CONTACT: All 

technical or programmatic questions 

concerning this announcement should 

be directed to Michael Guevara, 

Correctional Program Specialist, 

National Institute of Corrections. He can 

be reached by calling 303–365–4415, or 

by e-mail at mguevara@bop.gov. 

Questions will be accepted until one 

week prior to the application due date. 

At this time responses to the questions 

will be posted on the NIC Web site. 

SUPPLEMENTARY INFORMATION: 

Overview: NIC is looking to develop a 

curriculum, which follows NIC’s 

Instructional Theory Into Practice (ITIP) 

model, to be written based on 

occupational documentation that 

includes a completed DACUM 

(Developing A Curriculum) and a 


srobinson on DSKHWCL6B1PROD with NOTICES